# Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

> **NCT02443077** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 94 (actual)

## Conditions studied

- Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
- Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type

## Interventions

- **PROCEDURE:** Autologous Bone Marrow Transplantation
- **PROCEDURE:** Autologous Hematopoietic Stem Cell Transplantation
- **DRUG:** Carmustine
- **DRUG:** Cyclophosphamide
- **DRUG:** Cytarabine
- **DRUG:** Etoposide
- **DRUG:** Ibrutinib
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Melphalan
- **OTHER:** Pharmacogenomic Study
- **OTHER:** Placebo Administration

## Key facts

- **NCT ID:** NCT02443077
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-10-12
- **Primary completion:** 2024-06-10
- **Final completion:** 2026-12-23
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02443077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02443077, "Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02443077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*